Cipla Names Achin Gupta MD and CEO
Gupta, who currently serves as chief operating officer, will succeed Umang Vohra, who served as MD and Group CEO for nearly a decade.
Topics
News
- Firefox Enters AI Browser Race With New Opt-In Mode
- New Study Flags Growing Gap Between AI Plans and Data Readiness
- Anthropic Reports First Large-Scale Cyberattack Driven Mostly by AI
- Google’s New AI Wants to Do Your Holiday Shopping for You
- Parallel Secures $100 Million to Reimagine the Web for AI Agents
- IBM Adds Nighthawk and Loon to Its Quantum Portfolio
[Image source: Chetan Jha/MITSMR India]
Cipla Ltd, India’s third-largest drugmaker by sales, has announced the appointment of Achin Gupta as the next chief executive officer and managing director, with effect from 1 April 2026 for a tenure of five years.
Gupta, who currently serves as chief operating officer, will succeed Umang Vohra, who served as MD and Group CEO for nearly a decade.
“We are pleased to welcome Achin Gupta as he steps into this role, and I am confident he will lead Cipla to its next phase of progress and growth,” said Cipla chairman Y.K. Hamied.
As per regulatory filings, Vohra expressed his wish not to seek a re-appointment.
“My ten years at Cipla has been filled with immense pride in what we’ve built together…As I prepare to hand over the reins, I’m confident that Achin Gupta will lead Cipla forward with vision and purpose. I look forward to supporting him and the leadership team to ensure a smooth transition,” said Vohra.
Joining Cipla in 2021 as the CEO of the One India business, Gupta has been serving as global chief operating officer since February. He’s also appointed as an additional director.
Under his leadership, the India business delivered market-leading profitability, modernized its retail force, and introduced consumer-focused innovations, the company said.
He holds a M Tech degree from IIT-Delhi, specializing in Biochemical Engineering and Biotechnology, and an MBA from IIM-Ahmedabad.
“It is an honor to be entrusted with the responsibility of leading Cipla. Its legacy of purpose-driven innovation and patient-centric care is deeply inspiring, and I am committed to building on the strong foundation laid by Umang and the leadership team. As we move forward, my focus will remain on driving sustainable growth, deepening our impact across markets, and continuing to innovate with purpose,” said the incoming Cipla lead.
In its latest Q2FY26 earnings announcement, Cipla posted a 7.63% year-on-year surge in total revenue from operations to ₹7,589.44 crore in Q2FY26, against ₹7,051.02 crore in the September quarter of FY25.
